Article
BRAF V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Sept 2018
Wang Fei, Zhao Shihua, Shen Xiaopei, Zhu Guangwu, Liu Rengyun, Viola David, Elisei Rossella, Puxeddu Efisio, Fugazzola Laura, Colombo Carla, Jarzab Barbara, Czarniecka Agnieszka, Lam Alfred K, Mian Caterina, Vianello Federica, Yip Linwah, Riesco-Eizaguirre Garcilaso, Santisteban Pilar, O'Neill Christine J, Sywak Mark S, Clifton-Bligh Roderick, Bendlova Bela, Sýkorová Vlasta, Wang Yangang, Xing Mingzhao
Abstract excerpt
Purpose To test whether the prognostic risk of male sex in papillary thyroid cancer (PTC) is determined by BRAF V600E and can thus be stratified by BRAF status. Patients and Methods We retrospectively investigated the relationship between male sex and clinicopathologic outcomes in PTC, particularly mortality, with respect to BRAF status in 2,638 patients (male, n = 623; female, n = 2,015) from 11 centers in six...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.